To understand why the correspondence matters, it helps to unpack the diagnostic category at its center. The 2021 fifth edition of the WHO classification of tumors of the central nervous system reorganized diffuse gliomas around molecular features, most importantly mutations in the isocitrate dehydrogenase genes. Under the new framework, a diffuse astrocytic tumor without an IDH mutation is classified as astrocytoma, IDH-wildtype, and in adults this molecular profile places the tumor in the same family as glioblastoma. That shift left a residue of tumors that were diagnosed years ago as grade 2 or grade 3 diffuse astrocytomas on histology alone, before molecular testing was routine, but which are now understood to be IDH-wildtype. Carriere and colleagues examined the long-term outcomes of exactly this group, and their findings carry weight for the many patients whose archived diagnoses are being retrospectively reinterpreted.

The Paris authors’ central claim is that the companion study, and much of the literature surrounding it, has overlooked a variable that has been sitting in plain sight on every diagnostic scan: whether the tumor takes up gadolinium contrast. On a contrast-enhanced MRI, gadolinium normally stays within blood vessels because the blood-brain barrier keeps large molecules out of brain tissue. When a tumor disrupts that barrier, contrast leaks into the lesion and the region lights up on T1-weighted images. That enhancement is not a random artifact; it is a macroscopic signature of vascular proliferation and barrier breakdown, processes that correspond to aggressive biological behavior. In glioma practice, enhancement has long been one of the most scrutinized features on any scan.

The evidence base for that scrutiny is substantial, and the correspondence anchors its argument in three prior studies from overlapping author groups. The earliest, published by Pallud and colleagues in Neuro-Oncology in 2009, examined the prognostic significance of imaging contrast enhancement in WHO grade II gliomas and found that enhancement carried prognostic weight in these low-grade tumors. A second study, published by Roux and colleagues in Brain Pathology in 2020, asked whether adding MRI data improved the prognostic models built on the WHO 2016 classification and the cIMPACT-NOW updates for diffuse astrocytic tumors in adults, working toward the extended use of MRI data in integrated glioma diagnosis. A third, published by Roux and colleagues in the Journal of Neuro-Oncology in 2024, demonstrated the prognostic significance of MRI contrast enhancement in newly diagnosed glioblastoma, IDH-wildtype, according to the WHO 2021 classification.

Read together, those three studies trace a consistent thread across the modern diagnostic eras. Enhancement matters in tumors that look low-grade under the microscope. It matters when imaging features are layered on top of molecular and histological classifications to refine prognosis. And it matters even within glioblastoma, IDH-wildtype, where all patients already carry the worst prognostic label in neuro-oncology and yet enhancement still separates groups with different outcomes. The correspondence argues that the logical next step is to apply the same lens to the historical grade 2 and grade 3 IDH-wildtype gliomas that Carriere and colleagues analyzed, because these tumors sit precisely at the intersection where the prior evidence converges.

The stakes of that omission are easiest to see in the numbers that clinicians quote at the bedside. Historical grade 2 and grade 3 diffuse astrocytomas were traditionally described as indolent or moderately aggressive tumors with survival measured in many years, and counseling for newly diagnosed patients was built on those expectations. IDH-wildtype biology erodes that optimism considerably, because tumors in this molecular group behave more like glioblastomas even when their histology appears lower grade. If a patient’s tumor is reclassified retrospectively as IDH-wildtype astrocytoma, the prognostic conversation changes dramatically. But within that reclassified population, outcomes are unlikely to be uniform, and the correspondence suggests that contrast enhancement is one of the variables most likely to capture that heterogeneity.

The biological rationale for expecting enhancement to stratify these tumors is straightforward. Enhancement reflects disruption of the blood-brain barrier and, in gliomas, is closely associated with microvascular proliferation, one of the histological hallmarks that traditionally pushed a tumor toward a higher grade. A histologically grade 2 or grade 3 appearing tumor that nonetheless shows contrast enhancement is, in effect, displaying imaging evidence of aggressive vascular biology that the microscope may have undersampled. Diffuse gliomas are notoriously heterogeneous, and a small surgical specimen can miss foci of higher-grade biology elsewhere in the lesion. Enhancement on MRI offers a whole-tumor view that histology from a biopsy or even a resection cannot match, which is precisely why the authors describe it as a missing variable rather than a redundant one.

There is also a practical dimension to the argument that extends beyond prognosis. Treatment decisions for diffuse lower-grade gliomas, including the timing of surgery, the extent of resection attempted, and the threshold for adding radiotherapy and chemotherapy, are calibrated to expected tumor behavior. If enhancement identifies a subset of histologically lower-grade, IDH-wildtype tumors that behave like glioblastomas, those patients might warrant more intensive surveillance and earlier aggressive treatment, while patients with non-enhancing tumors might safely remain on the watch-and-wait pathways that have transformed quality of life in genuinely indolent glioma care. Conversely, trials that enroll historical grade 2 and 3 IDH-wildtype tumors as a single cohort risk diluting their results if enhancement status is not recorded and controlled for, because the cohort would mix biologically distinct populations.

The correspondence also lands at a moment when the field is actively debating how much imaging should be formalized in glioma classification. The 2021 WHO edition made molecular markers the backbone of diagnosis, but it stopped short of requiring specific imaging features, leaving radiological findings as contextual information rather than diagnostic criteria. Studies such as the 2020 Brain Pathology work argue that MRI data add prognostic value on top of molecular and histological categories, and the 2024 glioblastoma study shows that even within a single molecular class, imaging separates meaningful subgroups. The Paris authors’ commentary pushes that logic one step further: for the growing population of retrospectively reclassified IDH-wildtype tumors, imaging variables may be the most practical tool available to recover prognostic granularity that histology alone no longer provides.

None of this diminishes the contribution of the Carriere study, which the correspondence treats as a valuable foundation rather than a flawed analysis. Long-term outcome data for historical grade 2 and 3 IDH-wildtype gliomas are exactly what the field needs as archived diagnoses are revisited under the molecular era’s framework. The authors’ point is additive: those outcomes should be reanalyzed, and future cohorts should be analyzed from the start, with contrast enhancement as an explicit stratification variable. As hospitals increasingly re-review historical specimens with modern molecular panels, thousands of patients will find themselves in this reclassified category, and the questions their clinicians ask will hinge on which prognostic variables were captured. A variable as routinely available as contrast enhancement, the correspondence argues, should not be the one that gets away.

Subject of Research: Prognostic value of MRI contrast enhancement in IDH-wildtype gliomas with historical WHO grade 2 and 3 histology

Article Title: Contrast enhancement: the missing imaging variable in IDH-wildtype gliomas with historical WHO grade 2 and 3 histology

Article References: Roux, A., Zanello, M., & Pallud, J. (2026). Contrast enhancement: the missing imaging variable in IDH-wildtype gliomas with historical WHO grade 2 and 3 histology. Journal of Neuro-Oncology, 179(2), Article 74. https://doi.org/10.1007/s11060-026-05791-1

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05791-1

Keywords: glioma, IDH-wildtype, contrast enhancement, MRI, WHO classification, WHO grade 2, WHO grade 3, prognosis, neuro-oncology, blood-brain barrier, glioblastoma, neuroradiology

Lower-grade gliomas occupy an uneasy middle ground in neuro-oncology. They can smolder quietly for years, sometimes over a decade, allowing patients to work, drive and live largely normal lives under watchful surveillance. Yet nearly half of the patients in the new cohort — 77 of 155 — eventually underwent malignant transformation, the biological inflection point in which a slow-growing tumor acquires the aggressive behavior of a high-grade glioma and drives prognosis, adjuvant-therapy decisions and eligibility for clinical trials. Predicting which tumors will take that turn, and when, has remained one of the field’s most stubborn uncertainties, largely because transformation can only be pinned down retrospectively, at the moment a confirmatory MRI or a repeat biopsy reveals it.

The Austrian-led team attacked this problem from several angles simultaneously. Every patient had histologically confirmed adult-type diffuse glioma, diagnostic-quality multiparametric MRI including pre- and post-contrast T1, T2 and FLAIR sequences, and at least one follow-up scan. The time origin for each patient was the first MRI showing the glioma — a deliberately chosen anchor, since 18 patients in the cohort were managed with a wait-and-see strategy for more than a year, with one waiting 17.3 years before histological confirmation, contributing their untreated natural history to the analysis. Because malignant transformation is only ascertainable between examinations, the researchers bracketed each event within an interval bounded by the last documentation of low-grade status and the first examination showing transformation, rather than falsely assigning the event to a single scan date.

That methodological choice mattered enormously. When the team compared conventional dating — which treats the confirmatory scan as the moment of transformation — with proper interval-censored analysis, the conventional approach overstated the hazard of transformation roughly four-fold. The finding exposes a systematic bias running through much of the existing literature, where standard right-censored Cox models equate radiological detection with biological occurrence, an error whose magnitude grows with the length of the surveillance interval. To ensure their conclusions were not artifacts of any single statistical specification, the investigators cross-checked the primary Bayesian interval-censored Weibull model, fitted with a regularized horseshoe prior across 102 candidate predictors, against three frequentist alternatives: a Fine-Gray subdistribution-hazards model accounting for the competing risk of death without transformation, a Cox counting-process model handling surgery as a time-varying covariate with 20-fold multiple imputation, and a native interval-censored Fine-Gray model estimated by sieve maximum likelihood. All four agreed on the direction and significance of the central result.

And that central result was striking. Contrast enhancement visible on the diagnostic scan — even the subtle, sub-threshold kind that does not itself meet radiological criteria for malignancy — was by far the strongest predictor of subsequent malignant transformation, dwarfing both tumor volume and a co-analyzed panel of 99 quantitative radiomic features. In the full cohort, the Bayesian hazard ratio for enhancement reached 22.1, with a 95 percent credible interval of 10.5 to 53.2. Within IDH-mutant disease the association approached separation: all 22 enhancing tumors eventually transformed, compared with only 30 percent of non-enhancing ones, a pattern so extreme that the statisticians had to deploy Firth penalized-likelihood and exact conditional methods to obtain interpretable lower bounds. The same held true across every molecular entity represented — IDH-mutant astrocytomas, 1p/19q-codeleted oligodendrogliomas and IDH-wildtype tumors — with every single enhancing tumor in each subgroup ultimately transforming.

Critically, the team recognized that much of this dramatic unadjusted effect reflects tumors that were already transforming at or near diagnosis, so they performed a prespecified series of landmark analyses that condition on surviving transformation-free for three, six or twelve months and restart the clock there. Even under this stricter framing, a five- to seven-fold elevation in hazard persisted at every landmark: 7.41 at three months, 5.65 at six months and 6.33 at twelve months. The authors note that an unmeasured confounder would need an implausibly strong association with both enhancement and transformation — a risk ratio of at least 5.8 with each — to explain away the six-month estimate. Blinded re-reading of baseline scans by two independent reviewers achieved perfect agreement on enhancement status, and sensitivity analyses excluding patients who would meet the 2021 WHO grade 4 criteria left the effect essentially unchanged.

Perhaps the most surprising discovery concerned what happened after surgery. Because the exposure and the endpoint are both read from post-contrast imaging, one might suspect the enhancement signal simply marks a focus of high-grade disease that a resection removes. The data say otherwise. In a model of time from first surgery restricted to the 128 patients who had not transformed beforehand, baseline enhancement predicted post-surgical malignant transformation with a hazard ratio of 4.28 — and the effect not only persisted within gross-totally resected tumors, where any enhancing tissue present at baseline should have been removed, but strengthened under multivariable adjustment, rising to 7.58 when grade, IDH status and extent of resection were accounted for. Seven of eight enhancing tumors resected gross-totally still transformed, versus only 15 of 60 non-enhancing ones. A signal that outlives the very tissue generating it, the authors argue, points to a property of the tumor as a whole — an intrinsic biology — rather than a discrete focus awaiting excision.

Surgery itself emerged as the only modifiable determinant in the study. Gross-total resection was associated with a roughly two-thirds reduction in the post-surgical hazard of transformation compared with biopsy (hazard ratio 0.32), a benefit also seen within IDH-mutant disease, while subtotal resection showed no significant advantage over biopsy. The finding reinforces the current standard of early onco-functional resection in diffuse glioma, though the authors are careful to note that the timing of surgery in their retrospective cohort was confounded by indication — surgeons often operated precisely because early signs of transformation appeared — and cannot be interpreted causally. What they do propose is that baseline enhancement, currently discarded once histology becomes available, should be carried forward into postoperative risk estimation, where it independently refines prognostication alongside grade, molecular status and resection extent.

The study also delivered a sobering verdict on radiomics. Despite extracting 428 features from co-registered image volumes, reduced to 99 candidates by correlation filtering, not a single quantitative feature survived Bayesian horseshoe shrinkage or native interval-censored analysis. One texture feature retained significance only under the biased midpoint-imputation framework, collapsing to null under proper censoring — a conditional null the authors frame honestly, acknowledging that 77 events cannot credibly support 99 candidate biomarkers, and calling for radiomics discovery to be re-scoped toward predefined panels or much larger cohorts. With a bootstrap-corrected concordance of 0.83 but imperfect absolute-risk calibration, the team explicitly declines to offer their model for individual prediction. Instead, they position the work as a recalibration of the field’s foundations: contrast enhancement on the diagnostic scan deserves a central place in pre- and postoperative risk stratification, gross-total resection materially changes the transformation hazard, and any future estimate of when a lower-grade glioma will turn malignant should respect the interval-censored reality of how that event is actually observed.

Subject of Research: Predictors and timing of malignant transformation in lower-grade glioma using interval-censored survival analysis

Article Title: Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis

Article References: Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis. (n.d.). https://doi.org/10.1007/s11060-026-05803-0

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05803-0

Keywords: lower-grade glioma, malignant transformation, contrast enhancement, MRI, extent of resection, gross-total resection, interval censoring, Bayesian analysis, radiomics, IDH status, WHO classification, brain tumor